<div id="readability-page-1"><p>Peachtree Investment Partners LLC cut its position in  Eli Lilly and Company (NYSE:LLY - Free Report) by 7.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,627 shares of the company's stock after selling 1,984 shares during the quarter. Eli Lilly and Company makes up  about  7.4% of Peachtree Investment Partners LLC's holdings, making the stock its 3rd biggest position. Peachtree Investment Partners LLC's holdings in Eli Lilly and Company were worth $19,784,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>Which Healthcare Stock Is the Best Buy Right Now?</li></ul><p>Other hedge funds and other institutional investors also recently made changes to their positions in the company. Swisher Financial Concepts Inc. grew its position in shares of  Eli Lilly and Company by 7.7% during the 4th quarter. Swisher Financial Concepts Inc. now owns 1,187 shares of the company's stock worth $916,000 after buying an additional 85 shares during the period.  Bank of Nova Scotia lifted its stake in  Eli Lilly and Company by 94.3% in the fourth quarter. Bank of Nova Scotia now owns 366,407 shares of the company's stock valued at $282,885,000 after buying an additional 177,831 shares during the period.  Shelton Capital Management grew its position in shares of  Eli Lilly and Company by 6.1% during the 4th quarter. Shelton Capital Management now owns 17,821 shares of the company's stock worth $13,758,000 after buying an additional 1,032 shares during the period.  Rollins Financial Advisors LLC increased its stake in shares of  Eli Lilly and Company by 1.1% in the 4th quarter. Rollins Financial Advisors LLC now owns 1,732 shares of the company's stock valued at $1,337,000 after acquiring an additional 19 shares during the last quarter.  Finally, Rathbones Group PLC raised its position in shares of  Eli Lilly and Company by 20.9% in the 4th quarter. Rathbones Group PLC now owns 189,746 shares of the company's stock valued at $146,484,000 after acquiring an additional 32,850 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds. </p><h2>Analyst Upgrades and Downgrades</h2><p>LLY has been the subject of a number of analyst reports. Morgan Stanley  set a $1,146.00 price objective on shares of Eli Lilly and Company in a report on Thursday, March 6th. Leerink Partners  set a $950.00 target price on shares of Eli Lilly and Company in a report on Friday, January 17th. Citigroup reduced their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, January 28th. StockNews.com raised shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Friday, February 7th. Finally, Berenberg Bank  set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Three research analysts have rated the stock with a hold rating and seventeen have assigned  a buy rating to the company's stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $1,009.72.</p><ul><li>Price Targets Show These 3 Stocks Near the $1 Trillion Mark</li></ul><p><b>Get Our Latest Stock Analysis on LLY</b></p><h2>Insider Buying and Selling</h2><p>In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.13% of the stock is currently owned by company insiders. </p><h2>Eli Lilly and Company Stock Down 2.2 %</h2><ul><li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li></ul><p>Shares of LLY opened at $722.03 on Tuesday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The firm's 50 day moving average is $846.64 and its 200-day moving average is $830.05. The stock has a market capitalization of $684.61 billion, a PE ratio of 61.66, a P/E/G ratio of 1.40 and a beta of 0.51. </p><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%.  Equities research analysts forecast that  Eli Lilly and Company will post 23.48 EPS for the current year. </p><p>Eli Lilly and Company declared that its board has initiated a share buyback plan on Monday, December 9th that allows the company to repurchase $15.00 billion in  outstanding  shares. This repurchase authorization allows the company to reacquire up to 2% of its stock  through open market purchases. Stock  repurchase plans are usually an indication that the company's leadership believes its stock is undervalued. </p><h2>Eli Lilly and Company Company Profile</h2> (Free Report)<p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>Stock Sentiment Analysis: How it Works</li><li>Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains?</li><li>Are Penny Stocks a Good Fit for Your Portfolio?</li><li>Can NIO Overcome U.S.-China Tariff Headwinds?</li><li>How to start investing in penny stocks</li><li>Dow's Nuclear Gamble: A Bold Step in Turbulent Times</li></ul><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Peachtree Investment Partners LLC reduced its stake in Eli Lilly and Company (NYSE: LLY) by 7.2% in Q4, now holding 25,627 shares valued at approximately $19.78 million. Other institutional investors also adjusted their positions, with notable increases from Bank of Nova Scotia and Rathbones Group PLC. Eli Lilly's stock has received multiple analyst upgrades, with a consensus price target of $1,009.72. The stock is currently down 2.2%, trading at $722.03, with a market cap of $684.61 billion.</p>

Peachtree Investment Partners LLC Has $19.78 Million Stock Position in Eli Lilly and Company (NYSE:LLY)